MFDS medical device approvals January 2026

Overview

In January 2026, the Ministry of Food and Drug Safety (MFDS) approved four Medical Device Clinical Trial applications. Compared with high-activity months, the total count was more selective, yet the approved portfolio shows a broad spread of device modalities—from a neuropsychiatric device trial in major depressive disorder, to an injectable tissue repair biomaterial for nasolabial folds, a multicenter spinal fusion study evaluating bone graft materials in TLIF for lumbar degenerative disc disease, and an alexandrite laser study for facial lentigines.

This mix indicates that Korea’s MFDS pathway continues to support both therapeutic and aesthetic device development, including confirmatory (non-inferiority) designs and investigator/evaluator-blinded methodologies—patterns that matter when sponsors plan evidence packages for MFDS submission and downstream global expansion.

January 2026 Approval Highlights

• Total MFDS approvals: 4 Medical Device Clinical Trial projects
• Product diversity: 4 approvals across four distinct product categories (no single category dominated)
• Clinical focus areas represented:
  • Neuropsychiatry / CNS (Major Depressive Disorder)
  • Aesthetics (nasolabial folds; facial lentigines)
  • Orthopedics / Spine (Lumbar DDD; TLIF fusion)
• Study-design signals: presence of randomized, blinded, non-inferiority and multicenter designs—suggesting Korea’s ecosystem supports both early exploratory and confirmatory evidence generation.

Approvals by Product Category

Figure 1: MFDS-approved Medical Device Clinical Trial approvals by product category in Jan 2026.
Each category recorded one approval—showing an evenly distributed innovation pattern.

January’s approvals can be grouped into four product categories:

1. Physical Examination Device (Soricle) – evaluated for improving depressive symptoms in major depressive disorder patients (single-center, prospective, randomized, single-blind, active device-controlled, parallel, exploratory).
2. Biomaterial for Tissue Repair (MTP55) – compared with Juvederm® Ultra Plus XC for temporary improvement of nasolabial folds (single-center, randomized, evaluator–subject blinded, paired, non-inferiority, confirmatory).
3. Composite Bone Graft Implant Material (NOVOSIS PUTTY comparator) – multicenter, prospective, randomized, subject/evaluator-blinded, non-inferiority confirmatory study in TLIF for lumbar degenerative disc disease.
4. Alexandrite Laser Surgical Device (Picoalex) – single-center, prospective, single-arm, evaluator-blinded, sponsor-initiated exploratory study for removal of facial lentigines.

Strategic interpretation:

Rather than a single technology wave (e.g., neuromodulation-heavy months), January’s pattern suggests MFDS approvals were spread across multiple mature clinical areas, where sponsors can generate practical, submission-ready clinical endpoints with clear comparators (e.g., Juvederm) and established procedures (e.g., TLIF).

Key Study Designs Worth Noting

Even with only four approvals, January included trial designs that are especially relevant for regulatory planning:

• Non-inferiority + confirmatory frameworks (e.g., biomaterial and spinal fusion studies)
  → signals MFDS readiness to evaluate evidence packages designed for competitive positioning and standard-of-care comparisons.
• Blinding in device trials (evaluator- and subject-blinded / evaluator-blinded)
  → highlights how sponsors can strengthen evidence credibility even when full double-blind designs are difficult in device settings.
• Multicenter execution (spine/bone fusion study)
  → indicates a route to build robust generalizability and support broader clinical adoption post-approval.

Industry Outlook and Practical Takeaways

January 2026’s MFDS device trial approvals reinforce three practical points for sponsors and CRO/regulatory teams:

1. Korea supports both therapeutic and aesthetic device development
   Device categories ranged from CNS/psychiatry to dermatology aesthetics—useful for sponsors building multi-portfolio submission pipelines.
2. Comparator strategy matters
   Trials referencing clear comparators (e.g., established dermal filler benchmarks; bone graft comparators) can produce more decision-ready evidence for MFDS review and payer/market discussions.
3. Evidence quality signals are getting stronger
   Non-inferiority, blinding, multicenter operation—these are hallmarks of submission-grade clinical evidence, not merely exploratory feasibility testing.

Conclution

Planning a Medical Device Clinical Trial in Korea? Contact us for MFDS submission strategy, protocol design support, and site feasibility—built for efficient execution and audit-ready evidence.